Candel Therapeutics
Needham
About Candel Therapeutics
Candel develops cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $50K – $100K
- Total funding: $521.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2026)
- Ticker: nasdaq:CADL
- Website: candeltx.com
- Phone: 6179165445
Industries & Categories
Biotechnology, Genetics, Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/candel-therapeutics-31050 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.